Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality

Rick L. Evans1, James V. Pottala2, Satoshi Nagata3 and Kristi A. Egland1,2*

Abstract

Background: Metastatic breast cancer (BCa) is most often diagnosed months after completion of treatment of the primary tumor when a patient reports physical symptoms. Besides a physical examination, no other alternative recurrence screening method is recommended for routine follow-up care. Detection of autoantibodies against tumor-associated antigens (TAAs) has demonstrated promise for distinguishing healthy women from patients diagnosed with primary BCa. However, it is unknown what changes occur to patient autoantibody levels during and after treatment.

Methods: Three serial blood draws were collected from 200 BCa patients: before treatment, 6 and 12 months after surgery. Patients were categorized according to treatment regimen, including surgery, chemotherapy, radiation, trastuzumab and hormonal therapies. The longitudinal samples were assayed for autoantibody responses against 32 conformation-carrying TAAs using a Luminex multiplex bead assay.

Results: The treatment modality groups that had the greatest decrease in autoantibody response levels were radiation + hormonal therapy; radiation + chemotherapy; and radiation + hormonal therapy + chemotherapy. For these three treatment groups, autoantibody responses against 9 TAAs (A1AT, ANGPTL4, CAPC, CST2, DKK1, GFRA1, GRN, LGALS3 and LRP10) were significantly reduced at 12 months after surgery compared to before treatment. One TAA, GRP78, had a significantly increased autoantibody response after 12 months.

Conclusions: Single treatment regimens alone did not significantly alter autoantibodies levels against the studied TAAs. Radiation treatment was the common denominator of the three most affected groups for significant changes in autoantibody response levels.

Keywords: Breast cancer, Autoantibodies, Tumor-associated antigens, Treatment modalities

Background

Early diagnosis of breast cancer (BCa) is critical for increased disease survival, both at the time of initial disease as well as for recurrence [1, 2]. Including all races, the 5-year survival rate for women diagnosed with local BCa is 99%. Survival declines to 84% for regional stage and plummets to 26% for distant stage [3–5].

* Correspondence: kristi.egland@sanfordhealth.org
1Cancer Biology Research Center, Sanford Research, Sioux Falls, SD, USA
2Sanford School of Medicine, University of South Dakota, 2301 East 60th Street North, Sioux Falls, SD 57104, USA
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
asymptomatic patients without clinical findings on physical examination [10]. By the time the metastases are identified by physical symptoms, the patient’s chances of surviving the disease are greatly diminished [11]. Lack of early detection of recurrence for asymptomatic patients is a factor in the inability to cure metastatic BCa.

Numerous previous studies have detected the presence of autoantibodies to various cancer proteins in BCa patients [12, 13]. Measurement of these autoantibodies could offer early detection of BCa recurrence before physical symptoms are apparent, which would have a monumental impact by giving patients the choice of appropriate treatment options at an earlier stage of disease [14]. We previously screened patient plasma samples for autoantibodies against 20 different tumor-associated antigens (TAAs) and compared the profiles to healthy autoantibodies against 20 different tumor-associated antigens (TAAs) and compared the profiles to healthy women utilizing an ELISA-based platform. The 20 antigens were selected from a membrane-associated polyribosomal cDNA library (MAPcL), which encodes membrane and secreted proteins highly expressed in BCa and should preferentially induce an antibody response in patients [15]. The conformation of membrane and secreted proteins is particularly important because discontinuous epitopes will only be present for antibody recognition when the antigen is folded properly. Expression constructs were generated to encode the extracellular portion of the TAA fused to rabbit Fc (rFc), and a eukaryotic expression system was developed to produce conformation-carrying antigens that are processed with post-translational modifications [16]. A panel of 7 conformation-carrying TAAs, consisting of ANGPTL4, DKK1, LGALS1, MUC1, GFRA1, GRN and LRRC15, was identified that in combination could discern newly diagnosed BCa patients from healthy controls with a 73% sensitivity and 76% specificity [16]. To continue in the development of this technology, the single-well ELISA-based autoantibody assay was transitioned to a multiplex Luminex platform. The Luminex xMAP microsphere technology (Luminex, Austin, TX) allows measurement of the interaction of patient autoantibodies with a panel of antigen biomarkers enabling quantitation across all biomarkers in a single well [17].

It is unknown what, if any, changes occur to a BCa patient’s autoantibody profile after the tumor is removed and treatment begins. Because the autoantibodies specifically recognize cancer antigens, the autoantibody response may decrease during and after treatment due to the reduced tumor burden in the body. To address this question, the multiplex bead assay was performed on serial blood draws of 200 newly diagnosed BCa patient samples. Autoantibody responses against 32 antigens were determined over the course of both time and treatment, including surgery, radiation, chemotherapy, antibody and hormonal therapies.

Methods
Plasmid construction and protein production
Details for construction of plasmids encoding rabbit Fc (rFc)-tagged tumor-associated antigens (TAAs) have been described previously [16]. Briefly, the extracellular domain of transmembrane proteins or the full-length sequence of secreted and intracellular proteins was cloned into pSecTag2-rabbit Fc or pFUSE-rFc1. These plasmids included a secretion signal, as well as a C-terminal rFc tag. The TAA-rFc plasmids were transfected into 293 T cells (catalogue # CRL-3216, ATCC, Manassas, VA) with Effectene (Qiagen, Valencia, CA), and the encoded proteins were secreted into the cell culture supernatant. Supernatants were harvested after transfection, and TAA-rFc content was measured with an anti-rFc sandwich ELISA.

Antibody coupling to Luminex xMAP magnetic beads
Goat anti-rabbit IgG Fc antibody (Jackson Immunoresearch, West Grove, PA) was coupled to Luminex xMAP beads utilizing the xMAP AbC Kit (Luminex, Austin, TX) according to the manufacturer’s instructions. Briefly, beads were activated with EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) and Sulfo-NHS (N-hydroxysulfosuccinimide) for 20 min. After washing with phosphate buffered saline (PBS, pH 7.4), anti-rFc antibody was added to the beads at a concentration of 20 μg per 1 × 10⁶ beads and incubated for 2 h shielded from light. The beads were washed again and stored at 4 °C shielded from light until use. Coupling was performed on 32 Luminex bead regions that can be mixed for use and distinguished in 32 different areas by a Luminex 100/200 instrument (Millipore).

Loading of tumor-associated antigen-rabbit Fc fusion proteins to Luminex beads
Beads coupled with the anti-rFc antibody were coated with each TAA-rFc fusion protein by incubation with the cell culture supernatant containing secreted TAA-rFc fusion protein. Each of the 32 TAA-rFc fusions was bound to one Luminex bead region. Beads were incubated with the fusion protein at 40 μg/10⁶ beads overnight at 4 °C. Beads were stored in PBS-TBN buffer (PBS with 0.1% bovine serum albumin, 0.02% Tween 20 and 0.05% sodium azide) at 4 °C in the dark until use.

Patients
Patients for this study were recruited from Sanford Health, Sioux Falls, SD. Patients newly diagnosed with any type of BCa and were 30 years of age or older were invited to participate. A 10 ml EDTA tube of blood was collected from each of 200 patients prior to mastectomy, lumpectomy, chemotherapy, radiation therapy, or other treatment (Table 1). The patient descriptions and collection methods have previously been described elsewhere.
Patients enrolled in the study were followed for 1 year after surgery, and blood draws were obtained at follow-up oncology visits at 6 and 12 months after surgery. Potential subjects were excluded from the study if they had been previously diagnosed with any type of cancer. The longitudinal blood samples were collected from 10/08/09 to 8/27/13. The Sanford Health IRB approved the clinical protocol and consent forms for this study. Written informed consent was obtained from all patients enrolled in the study.

### Plasma Collection and Storage

Plasma was collected in 10 ml EDTA tubes and centrifuged at 2000 × g for 10 min within 12 h of drawing. Plasma was stored at −80 °C until the assay for the autoantibodies.

### Multiplex Autoantibody Bead Assay

The beads were washed free of background fluorophores and incubated with primary antibody. After incubation, the beads were washed and incubated with secondary antibody. The beads were then analyzed on a Luminex 100/200 instrument, with a minimum of 100 events analyzed for each bead region. Each plate included a negative control, as well as a positive control standard for each autoantibody.

### Statistical Methods

Each 96-well plate had a negative control background and a positive control standard for each autoantibody. In addition, each patient had her baseline, 6 and 12 month samples analyzed in the same 96-well plate. For each autoantibody, the patient's median fluorescent intensity (MFI) value had its plate MFI background level subtracted and was then shifted by the minimum constant to make all values at least one. The value was then normalized by the ratio of the MFI for the standard over the mean standard MFI across all 8 plates. Lastly, the values were log transformed to stabilize the variance and produce a more symmetric distribution. This process provided the clinical protocol and consent forms for the study.

### Table 1: Patient Clinical and Pathological Characteristics

| Condition | Female (%) | Ever Smoker (%) | BMI (kg/m²) Mean (SD) | Current (%) | Never (%) | Past (%) | Family History Yes (%) | Tumor Type (%) | Tumor Max Dimension (cm) (%) | ER Positive (%) | PR Positive (%) | HER2 Amplification (%) | Triple Negative (%) | Lymph Node Involvement (%) |
|-----------|------------|-----------------|-----------------------|--------------|------------|----------|------------------------|----------------|-----------------------------|----------------|----------------|-----------------------------|-------------------|---------------------|
| Breast Cancer | 67% | 12% | 58.9 ± 11.4 | 97% | 60% | 29% | 58% | 74% | 26% | 36% | 35% | 29% | 86% | 74% | 66% | 8% | 27% | 12% | 24% |
| Matched Healthy Controls | 67% | 12% | 58.8 ± 11.3 | 97% | 60% | 29% | 58% | 74% | 26% | 36% | 35% | 29% | 86% | 74% | 66% | 8% | 27% | 12% | 24% |
each TAA was calculated across the plates for the positive and negative controls.

A repeated measure ANOVA was used to model the geometric mean changes from baseline for each autoantibody over time (i.e. 6 and 12 months) as an exploratory analysis, with a compound symmetry correlation structure. The models included all interactions among indicator variables for radiation, hormonal and chemotherapy with time. This approach included 183 out of 200 BCa patients in the primary analysis; the 17 patients given trastuzumab as part of their treatment consisted of 4 groups and were analyzed secondarily by examining their mean response profile. Point estimates and 95% confidence intervals (CI) were calculated for all 8 treatment combinations, which did not include trastuzumab, at 6 and 12 months in order to rank autoantibodies by the number of positive findings. Since each TAA had 16 (8 treatments at 6 and 12 months) point estimates tested, one false positive was expected for each TAA; therefore, the observed geometric mean changes were presented for autoantibody levels with 3 or more positive findings. A p-value < 0.05 was used to ascribe statistical significance, and SAS (Cary, NC) version 9.3 was used for all analyses.

### Results

Serial plasma samples were collected from 200 newly diagnosed BCa patients [16]. Characteristics of the 200 BCa patients enrolled in this study have been previously described by our laboratory, including demographic information, tumor size, tumor marker status, in situ versus invasive components and lymph node involvement (Table 1) [16]. Blood draws were acquired before treatment, 6 and 12 months after surgical resection of the primary tumor. To determine the patients’ autoantibody responses against cancer antigens over the course of treatment, 32 TAA-rFc fusion proteins consisting of 20 previously analyzed TAAs [16] and 12 newly selected cancer antigens were generated (Table 2). The initial 20 antigens were selected from the MAPcL, which encodes cancer antigens with minimal expression in normal tissues [15]. The additional 12 antigens were selected based on previous literature demonstrating an autoantibody response against the cancer protein, regardless of the protein localization [18–29]. For consistency, the eukaryotic expression system developed previously [16] was used to generate all of the TAA-rFc antigens for the multiplex immunoassay. Thirty-two sets of Luminex beads consisting of unique red/infrared emission spectra were coated with anti-rabbit IgG. The 32 TAA-rFc fusion proteins were attached to the coated Luminex beads followed by incubation with plasma samples acquired from patients before treatment, 6 and 12 months post surgery. The average inter-assay CV for the 32 autoantibody responses measured at baseline (before the start of treatment) with the Luminex multiplex bead platform were 11.1 and 11.4% for the low and high controls, respectively (Additional file 1).

Each subject was categorized based on the treatments received during the 12 months following initial diagnosis. All enrolled BCa patients in our study underwent surgery to remove the primary tumor, including a breast lumpectomy or mastectomy. In addition to surgery, treatment included combinations of hormonal therapies,

### Table 2 Tumor-associated antigens for generation of rFc fusion proteins

| Gene   | Accession #   | Signal Sequence Amino Acids | Encoded Amino Acid Fragment |
|--------|---------------|-----------------------------|----------------------------|
| ANGPTL4| NM_139314     | 1–30                        | 31–406                     |
| CD147  | NM_198589     | 1–21                        | 22–162                     |
| CD320  | NM_016579     | 1–46                        | 47–230                     |
| CDH3   | NM_001793     | 1–24                        | 25–654                     |
| CST2   | NM_001322     | 1–20                        | 21–141                     |
| DK1    | NM_012242     | 1–28                        | 29–266                     |
| EPHA2  | NM_004431     | 1–26                        | 27–535                     |
| GFRA1  | AF038421      | 1–24                        | 25–465                     |
| GRN    | NM_002087     | 1–17                        | 18–593                     |
| ERBB2  | NM_004488     | 1–22                        | 23–652                     |
| IGFBP2 | NM_000597     | 1–39                        | 40–328                     |
| LAMC2  | NM_005562     | 1–21                        | 22–1111                    |
| LGALS1 | NM_002305     | 1–17                        | 18–135                     |
| LRP10  | NM_014045     | 1–16                        | 17–440                     |
| LRC15  | NM_00135057   | 1–27                        | 28–544                     |
| MUC1   | NM_002456     | 1–22                        | 23–167                     |
| SPINT2 | NM_021102     | 1–27                        | 28–198                     |
| SPO2   | NM_012445     | 1–26                        | 27–331                     |
| SSR2   | NM_003145     | 1–17                        | 18–146                     |
| SUSD2  | NM_019601     | 1–27                        | 28–785                     |
| A1AT   | NM_002954     | 1–24                        | 25–418                     |
| AMACR  | NM_014324.5   | None                        | 1–382                      |
| BIRC5  | NM_001168.2   | None                        | 1–142                      |
| CALD1  | NM_033139.3   | None                        | 1–558                      |
| CAPC   | NM_00136552.2 | 1–26                        | 27–264                     |
| CCNB1  | NM_031966.3   | None                        | 1–433                      |
| CCND1  | NM_053056.2   | None                        | 1–295                      |
| GRP78  | NM_005347.4   | None                        | 1–654                      |
| LGALS3 | NM_002306.3   | None                        | 1–250                      |
| MYC    | NM_002467.4   | None                        | 1–439                      |
| NY-ESO-1| NM_001327.2  | None                        | 1–180                      |
| XAGE1  | NM_001097594.2| None                        | 1–81                       |
trastuzumab, radiation and cytotoxic chemotherapy (Table 3). Seventy-two patients received cytotoxic chemotherapy consisting of one of the following regimens: adriamycin/cytotoxic + taxol = 33 patients; cytoxan + taxol = 22 patients; adriamycin/cytotoxic = 5 patients; carboplatin + taxol = 6 patients; adriamycin + cytoxan/taxol = 3 patients; adriamycin/cytotoxic + carboplatin/Gemzar = 1 patient; carboplatin + taxotere + novantrone = 1 patient; taxol alone = 1 patient. If a patient had any one of the chemotherapy regimens described above, they were considered part of the chemotherapy treatment group. Grouping the study participants based on treatment regimen resulted in 12 groups, ranging from no treatment after surgery to all treatment modalities administered (Table 3). Eight of the 12 groups received a combination of at least two therapies in addition to surgery. Three groups received a single therapy in addition to surgery, and one group received surgery alone.

Four of the 12 treatment groups received trastuzumab therapy (17 patients total, Table 3). Trastuzumab is a humanized monoclonal antibody that is generally administered every 3 weeks for 1 year to patients with amplification of the ERBB2 gene [30]. Since ERBB2 is one of the TAAs included in our assay, the treatment of these patients with trastuzumab provided a fortuitous internal spiked control. We determined the signal levels of the serial blood draws against ERBB2 for the 17 patients. Two main response patterns were observed correlating with time of trastuzumab administration. First, for patients that had discontinued trastuzumab therapy after 6 months, their anti-ERBB2 antibody responses for the 12-month blood draws decreased (Fig. 1, represented by patients BC-082 and BC-149). The second pattern is represented by patients BC-018 and BC-019 in Fig. 1. These patients continued to receive trastuzumab during the longitudinal blood draws, and the anti-ERBB2 antibody response against the ERBB2 antigen plateaued between the 6 and 12-month visits (Fig. 1).

For the primary exploratory analysis, we excluded the 17 patients who received trastuzumab as part of their therapy. Therefore, the analysis included 183 out of 200 patients and encompassed 8 of 12 patient treatment groups (Table 3). A repeated measure ANOVA was used to model the geometric mean changes from baseline for each autoantibody at 6 and 12 months, and the model included all interactions among indicator variables for radiation, hormonal therapy and chemotherapy with time. If the ANOVA model predicted at least 3 significant changes for an antigen among the 16 estimates (8 groups * 2 time points consisting of 6 and 12 month blood draws), it was chosen for further analysis. Using this variable selection criterion, the model identified 11 antigens that were likely to have significantly modulated autoantibody signals in response to treatment in the 12 months following surgery. The TAAs chosen for further study included: A1AT, ANGPTL4, CAPC, CST2, DKK1, GFRA1, GRN, GRP78, LGALS3, LRP10 and NY-ESO-1.

The actual geometric mean changes from baseline were calculated for the 11 TAAs at 6 months (Additional file 2) and 12 months (Fig. 2). No significant changes in the autoantibody response against the 11 antigens were observed for patients who received surgery alone or were treated with surgery and a single mono-therapy: hormonal therapy, chemotherapy or radiation.

![Fig. 1](image1.png) Representative antibody responses against ERBB2-fc in patients diagnosed with ERBB2 positive breast cancer treated with Trastuzumab. Three longitudinal blood draws were collected, immediately before surgery, 6 and 12 months after surgery. Patients BC-018 and BC-019 were still receiving Trastuzumab therapy at their 12-month visit, and patients BC-082 and BC-149 discontinued Trastuzumab therapy prior to their 12-month visit.

---

**Table 3** Number of patient blood draws per treatment modality and visit

| Treatment Group | Baseline | 6 Month | 12 Month | Subtotal |
|-----------------|----------|---------|----------|----------|
| Radiation + Hormonal | 59 (29.5%) | 52 | 52 | 163 |
| Hormonal | 31 (15.5%) | 25 | 26 | 82 |
| Radiation + Hormonal + Chemotherapy | 25 (12.5%) | 23 | 22 | 70 |
| Surgery Only | 24 (12.0%) | 15 | 10 | 49 |
| Hormonal + Chemotherapy | 15 (7.5%) | 12 | 13 | 40 |
| Radiation | 13 (6.5%) | 8 | 8 | 29 |
| Radiation + Chemotherapy | 11 (5.5%) | 11 | 11 | 33 |
| Radiation + Hormonal + Chemotherapy + Trastuzumab | 8 (4.0%) | 8 | 8 | 24 |
| Chemotherapy | 5 (2.5%) | 4 | 5 | 14 |
| Hormonal + Chemotherapy + Trastuzumab | 5 (2.5%) | 5 | 5 | 15 |
| Radiation + Chemotherapy + Trastuzumab | 3 (1.5%) | 2 | 2 | 7 |
| Radiation + Hormonal + Trastuzumab | 1 (0.5%) | 1 | 1 | 3 |
| Total number of samples | 200 (100%) | 166 | 163 | 529 |

*All patients received surgery to remove the primary tumor*
While NY-ESO-1 was predicted to have significant changes in levels of response in the repeated measures ANOVA model, the observed changes were not significant (Fig. 2). However, significant decreases in levels of response between baseline and 12 month time points against 9 of the 11 TAAs (i.e. A1AT, ANGPTL4, CAPC, CST2, DKK1, GFRA1, GRN, LGALS3 and LRP10) were observed in three treatment groups. Radiation + chemotherapy, radiation + hormonal therapy, and radiation + hormonal therapy + chemotherapy had average geometric mean decreases for the 9 significant TAA of −11, −13, and −18%, respectively (Fig. 2). In the radiation + hormonal therapy + chemotherapy group, A1AT and LRP10 had the greatest decrease in autoantibody response levels (−26 and −28%, respectively) compared to the other antigens and regimens. The triple therapy of radiation + hormonal + chemotherapy was more effective at reducing the autoantibody responses against the TAAs than any other combination of treatment. In addition, the decrease in response of the geometric mean was −15% at 6 months after surgery (Additional file 2) compared to a greater decrease of −18% at the 12-month time point (Fig. 2). It is apparent that autoantibody levels diminish during the course of treatment, and they continue to decrease with time as the patient is further removed from initial diagnosis. At the 12-month time point, GRP78 was the only TAA to exhibit a significantly increased autoantibody response of 44%, which occurred in the hormonal therapy + chemotherapy group (Fig. 2).

**Discussion**

Measurement of autoantibody responses to cancer proteins holds promise as a minimally invasive screening method in cancer diagnostics and prognostics. Numerous TAAs that elicit an immune response have been identified, and findings in this realm continue to expand [31–33]. Although studies have shown the presence of the autoantibodies at the time of BCa diagnosis [13, 34, 35], little is known about how these antibodies are maintained over time and affected by treatment. This study provides important data on longitudinal changes of autoantibody response occurring in BCa patients after surgery. We were able to assess 32 TAAs simultaneously with our unique multiplex bead assay. In addition, rich data on pathology and treatment information allows the findings of this study to be associated with the treatment regimens administered to each patient.

Patients in this study that were ERBB2-amplified received trastuzumab treatment, which recognizes and binds to a native pocket-like binding region of ERBB2 [36, 37]. As predicted, the levels of trastuzumab against ERBB2 in patient plasma correlated temporally with patient treatment (Fig. 1). To remove the confounding variable of trastuzumab treatment, patients treated with the anti-ERBB2 antibody were removed from the primary analysis. The data collected from the longitudinal blood draws indicated that significant changes in antibody responses were detected at the 6-month time point (Additional file 2), with a more extensive reduction detectable 12 months after the primary tumor was surgically resected and therapy initiated (Fig. 2). The absence of a large tumor mass is one explanation for the reduced production of autoantibodies to TAAs. With the majority of the cancer cells removed, the immune system would be exposed to fewer cancer antigens reducing the levels of autoantibody production. Alternatively, the decrease in autoantibody activity could be due to radiation + chemotherapy and/or hormonal therapy-induced immunosuppression. The fact that a single treatment modality after surgery, including radiation alone, did not alter the levels of autoantibodies indicates that it is not simply due to treatment-induced immunosuppression.
Surprisingly, we also found that treatments administered after the removal of the primary tumor had a profound effect on the autoantibody profile. GRP78 showed an increase in autoantibody signal at the 12-month time point in patients receiving chemotherapy followed by hormonal therapy. This protein is typically localized to the endoplasmic reticulum [38], but it has been shown to translocate to the cell surface in cancer cells [39], particularly in times of cellular stress [40]. The cellular stress imposed on tumor cells by anti-neoplastic treatments would explain a change in localization of GRP78 from the endoplasmic reticulum to the surface, making it more available to the immune system in its aberrant location. Production of anti-GRP78 antibodies could occur in this situation, explaining the outlying antibody increase obtained for this TAA.

There is one confounding factor that is difficult to overcome when attributing the data to the treatment groups: the treatment given to a patient is dictated by the physical characteristics of the tumor, i.e. the presence of the estrogen receptor, amplification of ERBB2, size of the tumor, in situ versus invasive components and lymph node involvement. The changes seen in these samples are attributed to the therapies administered to that patient, but it is acknowledged that these therapies are a function of the characteristics of each subtype of BCa [41, 42].

To that end, the treatment modality groups that had the greatest decrease in autoantibody response levels were radiation + hormonal therapy; radiation + chemotherapy; and radiation + hormonal therapy + chemotherapy (Fig. 2). The common denominator of the three most affected groups for significant changes in autoantibody response levels is radiation treatment. However, radiation treatment alone is not enough to significantly decrease the response levels of the autoantibodies (Fig. 2).

Four antigens (ANGPTL4, DKK1, GFRA1 and GRN) overlapped with the ability to discern BCa patients from healthy [16] and to elicit an autoantibody response against them that was significantly lowered over the course of treatment (Fig. 2). Yet, three of the seven previously characterized antigens (LGAL1, LRRC15 and MUC1) were not altered longitudinally in the current study. It is possible that these antigens only have utility in the initial diagnosis of BCa and do not exhibit a statistically significant reduction in autoantibody levels after treatment. Another explanation is that the 7 antigens utilized to discern health from cancer patients were analyzed as a group and not individual responses against each antigen.

The ultimate goal of detecting autoantibodies in the follow-up setting is to determine if the autoantibody response to a panel of cancer antigens can predict patient response to treatment and detect recurrence of the disease. Future studies will include acquiring serial blood draws before and after the patient presents with physical symptoms of recurrence. The fact that the autoantibody levels of BCa patients decrease over the course of treatment when radiation is used in combination treatment modalities supports the potential of using the detection of these autoantibody levels as a prognostic indication of recurrence.

Conclusions
Adjuvant treatment following the removal of the primary tumor had an extensive effect on the autoantibody profile of the patient. Autoantibody levels of BCa patients against TAAs decreased over the course of treatment when radiation was used in combination treatment modalities. Using a Luminex-based multiplex bead analysis, significant decreases in levels of response against A1AT, ANGPTL4, CAPC, CST2, DKK1, GFRA1, GRN, LGALS3 and LRP10 were observed between baseline and 12 month time points in three treatment groups: Radiation + chemotherapy, radiation + hormonal therapy, and radiation + hormonal therapy + chemotherapy. A significant increase in autoantibody response was observed against GRP78 in the hormonal therapy + chemotherapy group.

Additional files

Additional file 1: Table indicating inter-assay coefficients of variability (CV) for the Luminex multiplex immunoassay. Shown are the average inter-assay CV for the autoantibody responses against the 32 TAAs for negative and positive controls. Calculations were measured at baseline (before the start of treatment) using the Luminex multiplex bead platform. (DOCX 32 kb)

Additional file 2: Observed geometric mean changes of patients’ autoantibody responses at 6 months after the start of treatment. The graph indicates the observed geometric mean changes (with 95% confidence intervals) of autoantibody levels against 11 tumor-associated antigens according to treatment regimen after 6 months follow-up. *indicates p-value < 0.05. There were no significant changes observed for surgery only or individual therapies (i.e. hormonal, radiation, or chemotherapy). (DOCX 117 kb)

Abbreviations
BCa: Breast cancer; CI: Confidence interval; ELISA: Enzyme-linked immunosorbent assay; MAPcL: Membrane-associated polyribosomal cDNA library; MFI: Median fluorescence intensity; PBS: Phosphate buffered saline; PE: R-Phycocerythrin; rFc: Rabbit Fc; TAA: Tumor-associated antigen

Acknowledgements
We thank Jill Healy, RN for her dedication to this project and helping us consent patients into this study. Sanford Clinic - Surgical Associates was critical in helping us recruit patients. Donna Smithback, RN and Gloria Top, RN, breast oncology care coordinators, were essential for patient recruitment. We especially thank Colleen Wangness, Sanford Health Oncology Phlebotomist, for always remembering to take the extra tube of blood when patients came in for their follow-up appointments.

Funding
This research was supported by a grant from the NIH, NIGMS, Center of Biomedical Research Excellence (COBRE) grant, number P20 GM103548. KAE is a project leader on this grant. The funding source did not influence or participate in the design, sample collection, analysis, interpretation of data or writing of the manuscript.
Availability of data and materials
All datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
RE performed all of the assays for this manuscript and was a major contributor in writing the first draft of the manuscript. JP analyzed and interpreted the patient data regarding autoantibody response against tumor antigens, prepared figures and wrote the statistical analysis portion of the manuscript. SN made substantial contributions to conception and design of the study and was involved in critically revising the manuscript. KE conceived the study and participated in its design, coordination and writing of the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
All patients provided written informed consent, and the Sanford Health IRB approved the study protocol.

Consent for publication
Not Applicable.

Competing interests
Authors RE, JP and KE and Sanford Research have a potential financial conflict of interest based on patent PCT/US2016/065893 filed and licensed to Inanovate, Inc., a small for-profit business. Sanford Research has an equity conflict of interest based on patent PCT/US2016/065893 filed and licensed to Authors RE, JP and KE and Sanford Research have a potential financial

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Cancer Biology Research Center, Sanford Research, Sioux Falls, SD, USA.
2Sanford School of Medicine, University of South Dakota, 2301 East 60th Street North, Sioux Falls, SD 57104, USA.
3Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki-City, Osaka 5670085, Japan.

Received: 16 September 2016 Accepted: 23 January 2018
Published online: 31 January 2018

References
1. Aragon R, Morgan J, Wong JH, Lum S. Potential impact of USPSTF recommendations on early diagnosis of breast cancer. Ann Surg Oncol. 2011;18(11):3137–42.
2. Kontos M, Roy P, Rizos D, Petrou A, Hamed H. Contralateral relapse after surgery for breast cancer evaluation of follow-up paradigms. Int J Clin Pract. 2013;67(11):1137-1143.
3. Siegel RL, DeSantis C, Moroson R, Aminou R, Eifel PJ, Ang K, et al. Cancer statistics review, 1975–2012. J Natl Cancer Inst. 2013;105(4):377-460.
4. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda: National Cancer Institute; 2015.
5. Carson RT, Vignali DA. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods. 1999;227(1–2):41–52.
6. Egland KA, Liu XF, Squires S, Nagata S, Man YG, Bera TK, Onda M, Vincent JJ, Strasburg RB, Lee B, et al. High expression of a cytokertatin-associated protein in many cancers. Proc Natl Acad Sci U S A. 2006;103(15):5929–34.
7. Fossa S, Aliseo L, Cramer F, Funderud S, Gudnaunder G, Smedb L. Serological cloning of cancer/testis antigens identified in patients with early-stage breast cancer. Electrophoresis. 2012;33(4):1230–7.
8. O’Rourke DJ, Johnson DA, Giazzo RJ Jr, Nelson JC, Ure D, O’Leary MP, Richie JP, Liu BC. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. Clin Chim Acta. 2010;411(8–9):556–7.
9. Xie C, Kim HJ, Hwang JG, Kalsal B, Gardner BK, Li G, Rao J, Chia D, Lu J, Punzalan RR, et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011;9:43.
10. Xu Y, Jin Y, Liu L, Zhang X, Chen Y, Wei J. Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer. FEBS Open Bio. 2015;5:198–201.
11. Yang Z, Chevotot Y, Gehr H, Solassol J, Mange A, Souteyrand E, Laurenceau E. Improvement of protein immobilization for the elaboration of tumor-associated antigen microarray: application to the sensitive and specific detection of tumor markers from breast cancer sera. Biosens Bioelectron. 2013;40(1):355–61.
12. Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, Qian W, Zhang J. Mini-array of multiple tumor-associated antigens (TAA) in the immunodiagnosis of breast cancer. J Biomed Biotechnol. 2012;2012:284371-5.
13. Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li B, Han XN, Xu JW, Zhao YX, Zhang P, et al. Autoantibody detection to tumor-associated antigens of PS3, MIP1, CCL1, P62, C-myc, Survivin, and Kic for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma. Dis Esophagus. 2014;27(8):790–7.
14. Zuo X, Chen L, Liu L, Zhang Z, Zhang Y, Yu Q, Feng L, Zhao X, Qin T. Identification of a panel of complex autoantigens (LGAL5, PHB2, MUC1, and GKI) in combination with CA15-3 for the diagnosis of early-stage breast cancer. Tumour Biol. 2015;37(1):1309–17.
15. Highlights of Prescribing Information [http://www.gene.com/download/pdf/herceptin_prescribing.pdf].
31. Heo CK, Bahk YY, Cho EW. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep. 2012;45(12):677–85.

32. Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang JY. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2011;10(6):331–5.

33. Zhu Q, Liu M, Dai L, Ying X, Ye H, Zhou Y, Han S, Zhang JY. Using immunoproteomics to identify tumor-associated antigens (TAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2013;12(12):1123–8.

34. Fernandez-Madrid F, Maroun MC. Autoantibodies in breast cancer. Adv Clin Chem. 2014;64:221–40.

35. Lu H, Goodell V, Dhis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 2008;7(4):1388–94.

36. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756–60.

37. Garret JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol. 2007;178(11):7120–31.

38. Haas IG. BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum. Experientia. 1994;50(11–12):1942–20.

39. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007;67(8):3496–9.

40. Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;32(7):805–18.

41. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

42. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.